<DOC>
	<DOC>NCT00406211</DOC>
	<brief_summary>Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' measles-mumps-rubella (MMR) vaccine (Priorix®) and varicella vaccine (Varilrix®) in Germany &amp; Austria. Blood samples were collected at three time points during the follow-up period (Year 1, 2 &amp; 3). No new subjects will be enrolled in these follow-up phases of the study.</brief_summary>
	<brief_title>Long-term Follow-up on Immunogenicity &amp; Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Written informed consent from the parents/guardians of the child before participating in the longterm followup. Subjects must have received their complete vaccination course according to the group allocation (i.e. subjects must have received either two doses of MMRV combined vaccine, or two doses of Priorix vaccine and one dose of Varilrix vaccine as separate injections in the primary vaccination study. Subjects were aged between 12 to 18 months of age at the time of the first vaccination in the primary study. Subjects must not have received an additional dose of measles, mumps, rubella or varicella containing vaccines.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rubella</keyword>
	<keyword>Varicella</keyword>
	<keyword>Measles</keyword>
	<keyword>Mumps</keyword>
	<keyword>Germany</keyword>
	<keyword>Austria</keyword>
</DOC>